StocksMedium•9 November 2026•
1 min read
Coherus Oncology Reports Q3 2026 Results and Unveils Strategic Pivot
Key Facts
1Coherus Oncology reported its Q3 2026 financial results and announced a strategic prioritization plan.
2The company plans to focus development efforts on tagmokitug/toripalimab as a potential treatment for esophageal cancer.
Coherus Oncology reported its Q3 2026 financial results and announced a strategic prioritization plan. According to a statement released via GlobeNewswire, the company plans to focus its development efforts on tagmokitug/toripalimab as a potential treatment for esophageal cancer to expedite development timelines.
The company reported a net loss from continuing operations of $38.9 million for the third quarter ended September 30, 2026, compared to a $44.5 million loss in the same period last year. CHRS closed at $0.77 on November 6, 2026, as the firm implements measures to lower its core cash burn by $6 million to $7 million quarterly over the next two quarters.